NKGen amends securities purchase agreement with Alpha to add 4.99% beneficial ownership cap

NKGen Biotech, Inc.

Amendment dated May 13, 2024 to the May 7, 2024 Securities Purchase Agreement with Generating Alpha Ltd.
New Section 4(x) prohibits issuance of common stock that would cause Alpha and affiliates to beneficially own more than 4.99% of outstanding shares.
Beneficial ownership determined per Section 13(d) of the Exchange Act and Regulation 13D-G.
All other terms of the original Purchase Agreement remain unchanged.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

NKGen Biotech, Inc. amended Amendment with Generating Apha Ltd. ("Alpha") (effective 2024-05-13).

Action: amendment
Agreement: equity purchase
Counterparty: Generating Apha Ltd. ("Alpha")
Effective: 2024-05-13

Exact text from the filing

On May 13, 2024, NKGen Biotech, Inc. (the “Company”) and Generating Apha Ltd. (“Alpha”) entered into an amendment (the “Amendment”) to the securities purchase agreement, dated as of May 7, 2024, between the Company and Alpha (the “Purchase Agreement”).

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001213900-24-041919

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.